SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Krenning Eric)
 

Sökning: WFRF:(Krenning Eric) > Impact of liver tum...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008711naa a2200949 4500
001oai:DiVA.org:uu-423870
003SwePub
008201110s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4238702 URI
0247 a https://doi.org/10.1007/s00259-020-04709-x2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Strosberg, Jonathanu H Lee Moffitt Canc Ctr & Res Inst, Neuroendocrine Tumor Div, Gastrointestinal Dept, Tampa, FL 33612 USA.4 aut
2451 0a Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate :b an analysis of the NETTER-1 study
264 c 2020-03-02
264 1b SPRINGER,c 2020
338 a electronic2 rdacarrier
520 a Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate. Methods In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results Significantly prolonged median PFS occurred with Lu-177-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the Lu-177-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions Lu-177-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. : NCT01578239, EudraCT: 2011-005049-11
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
653 a Lu-177-Dotatate
653 a Liver tumour burden
653 a NETTER-1
653 a Neuroendocrine tumour
653 a Octreotide
7001 a Kunz, Pamela L.u Stanford Univ, Med Ctr, Dept Med Med Oncol, Stanford, CA 94305 USA.4 aut
7001 a Hendifar, Andrewu Cedars Sinai Med Ctr, Dept Internal Med Hematol Oncol, Los Angeles, CA 90048 USA.4 aut
7001 a Yao, Jamesu Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.4 aut
7001 a Bushnell, Davidu Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.4 aut
7001 a Kulke, Matthew H.u Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.4 aut
7001 a Baum, Richard P.u Zent Klin Bad Berka, Dept Nucl Med, Bad Berka, Germany.4 aut
7001 a Caplin, Martynu Royal Free Hosp, Dept Gastroenterol & Tumour Neuroendocrinol, London, England.4 aut
7001 a Ruszniewski, Philippeu Hop Beaujon, Div Gastroenterol & Pancreatol, Clichy, France.4 aut
7001 a Delpassand, Ebrahimu Excel Diagnost Imaging Clin, Dept Clin Nucl Med, Houston, TX USA.4 aut
7001 a Hobday, Timothyu Mayo Clin, Coll Med, Dept Oncol, Rochester, MN USA.4 aut
7001 a Verslype, Chrisu Univ Hosp, Dept Hepatol, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium.4 aut
7001 a Benson, Alu Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL USA.4 aut
7001 a Srirajaskanthan, Rajaventhanu Kings Coll Hosp NHS Fdn Trust, Dept Gastroenterol & Gen Internal Med, London, England.4 aut
7001 a Pavel, Marianneu Charite Univ Med Berlin, Div Gastroenterol & Hepatol, Berlin, Germany.4 aut
7001 a Mora, Jaumeu Hosp Univ Bellvitge, Dept Nucl Med, Barcelona, Spain.4 aut
7001 a Berlin, Jordanu Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.4 aut
7001 a Grande, Enriqueu MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain.4 aut
7001 a Reed, Nicholasu Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland.4 aut
7001 a Seregni, Ettoreu Ist Nazl Tumori, Fdn Ist Ric & Cura Carattere Sci, Dept Nucl Med Therapy & Endocrinol, Milan, Italy.4 aut
7001 a Paganelli, Giovanniu IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy.4 aut
7001 a Severi, Stefanou IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy.4 aut
7001 a Morse, Michaelu Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.4 aut
7001 a Metz, David C.u Hosp Univ Penn, GI Div, 3400 Spruce St, Philadelphia, PA 19104 USA.4 aut
7001 a Ansquer, Catherineu Univ Hosp, Hotel Dieu, Dept Nucl Med, Nantes, France.4 aut
7001 a Courbon, Fredericu Oncol Univ, Inst Claudius Regaud, Med Imaging, Toulouse, France.4 aut
7001 a Al-Nahhas, Adilu Imperial Coll London, Div Imaging & Intervent Radiol, London, England.4 aut
7001 a Baudin, Ericu Inst Gustave Roussy, Dept Endocrine Oncol & Nucl Med, Villejuif, France.4 aut
7001 a Giammarile, Francescou IAEA, Dept Nucl Sci & Applicat, Vienna, Austria.4 aut
7001 a Taieb, Davidu Hop La Timone, Dept Nucl Med, Marseille, France.4 aut
7001 a Mittra, Eriku Oregon Hlth & Sci Univ, Dept Nucl Med, Portland, OR 97201 USA.4 aut
7001 a Wolin, Edwardu Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA.4 aut
7001 a O'Dorisio, Thomas M.u Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.4 aut
7001 a Lebtahi, Rachidau Royal Free Hosp, Dept Nucl Med, London, England.4 aut
7001 a Deroose, Christophe M.u Univ Hosp, Dept Nucl Med, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium.4 aut
7001 a Grana, Chiara M.u Ist Europeo Oncol, Div Nucl Med, Milan, Italy.4 aut
7001 a Bodei, Lisau Mem Sloan Kettering Canc Ctr, Dept Nucl Med, 1275 York Ave, New York, NY 10021 USA.4 aut
7001 a Öberg, Kjell,d 1946-u Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob
7001 a Polack, Berna Degirmenciu Adv Accelerator Applicat, Dept Med Informat, Geneva, Switzerland.4 aut
7001 a He, Beileiu Adv Accelerator Applicat, Geneva, Switzerland.4 aut
7001 a Mariani, Maurizio F.u Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut
7001 a Gericke, Germou Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut
7001 a Santoro, Paolau Adv Accelerator Applicat, Dept Clin Dev, Geneva, Switzerland.4 aut
7001 a Erion, Jack L.u Adv Accelerator Applicat, Geneva, Switzerland.4 aut
7001 a Ravasi, Laurau Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland.4 aut
7001 a Krenning, Ericu Erasmus Univ, Med Ctr, Cyclotron Rotterdam BV, Dept Nucl Med, Rotterdam, Netherlands.4 aut
7102 a H Lee Moffitt Canc Ctr & Res Inst, Neuroendocrine Tumor Div, Gastrointestinal Dept, Tampa, FL 33612 USA.b Stanford Univ, Med Ctr, Dept Med Med Oncol, Stanford, CA 94305 USA.4 org
7730 t European Journal of Nuclear Medicine and Molecular Imagingd : SPRINGERg 47:10, s. 2372-2382q 47:10<2372-2382x 1619-7070x 1619-7089
8564 u https://doi.org/10.1007/s00259-020-04709-xy Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1499957/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://link.springer.com/content/pdf/10.1007/s00259-020-04709-x.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423870
8564 8u https://doi.org/10.1007/s00259-020-04709-x

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy